COST IMPACT OF TAFASITAMAB COMBINED WITH LENALIDOMIDE AND RITUXIMAB IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: A TIME TO NEXT TREATMENT AND NUMBER NEEDED TO TREAT BASED PHARMACOECONOMIC ANALYSIS
Author(s)
Bruno Moreira de Almeida Marques, MBA1, Carolina Rosa Roque Simões Rollo, MBA2, Vitor Pontes Rocha, Msc, MBA3, Melina Campagnaro, MBA, PhD4.
1Knight Therapeutics, Cotia, Brazil, 2Market Access, Knight Therapeutics, Brazil, Brazil, 3Knight Therapeutics, São Paulo, Brazil, 4HEOR & Pricing Manager, Knight Therapeutics, São Paulo, Brazil.
1Knight Therapeutics, Cotia, Brazil, 2Market Access, Knight Therapeutics, Brazil, Brazil, 3Knight Therapeutics, São Paulo, Brazil, 4HEOR & Pricing Manager, Knight Therapeutics, São Paulo, Brazil.
OBJECTIVES: The management of relapsed or refractory follicular lymphoma (R/R FL) has rapidly evolved with the introduction of targeted agents and novel immunotherapies, many of which are associated with substantial costs. This study aimed to assess the economic impact of alternative second-line (2L) treatment sequences in R/R FL, with a focus on tafasitamab combined with lenalidomide and rituximab (R²). Time to next treatment (TTNT) was used to derive the number needed to treat (NNT) and to estimate cost offsets associated with delaying or preventing progression to subsequent high-cost therapies.
METHODS: A cost-impact analysis was conducted for 2L R/R FL, incorporating therapeutic options recommended in clinical guidelines. Three treatment strategies were evaluated: tafasitamab + R², R² alone, and epcoritamab + R². Progression to third-line therapy with epcoritamab was modeled to capture downstream costs. NNT was derived from TTNT based on Kaplan-Meier estimates, using the median follow-up reported in the inMIND study as the analytical time horizon.
RESULTS: The total treatment cost for tafasitamab + R² was estimated at BRL 1,134,778.96, compared with BRL 1,324,423.09 for epcoritamab + R². Over an approximately 14-month period, an absolute risk reduction of 15% in progression to subsequent therapy was observed, corresponding to an NNT of 7. This translates into approximately 15 fewer progressions per 100 treated patients. Progression following epcoritamab therapy was associated with an estimated cost of BRL 1,360,213.07 per patient, including drug acquisition and dose wastage. In a simulation of 100 patients, the observed NNT suggests that 15 progressions could be avoided, yielding an estimated gross cost offset of approximately BRL 19 million.
CONCLUSIONS: A pharmacoeconomic framework incorporating TTNT and NNT enables quantification of the economic value of tafasitamab in 2L R/R FL. By reducing progression to costly subsequent therapies, this strategy has the potential to mitigate overall budget impact across the treatment journey.
METHODS: A cost-impact analysis was conducted for 2L R/R FL, incorporating therapeutic options recommended in clinical guidelines. Three treatment strategies were evaluated: tafasitamab + R², R² alone, and epcoritamab + R². Progression to third-line therapy with epcoritamab was modeled to capture downstream costs. NNT was derived from TTNT based on Kaplan-Meier estimates, using the median follow-up reported in the inMIND study as the analytical time horizon.
RESULTS: The total treatment cost for tafasitamab + R² was estimated at BRL 1,134,778.96, compared with BRL 1,324,423.09 for epcoritamab + R². Over an approximately 14-month period, an absolute risk reduction of 15% in progression to subsequent therapy was observed, corresponding to an NNT of 7. This translates into approximately 15 fewer progressions per 100 treated patients. Progression following epcoritamab therapy was associated with an estimated cost of BRL 1,360,213.07 per patient, including drug acquisition and dose wastage. In a simulation of 100 patients, the observed NNT suggests that 15 progressions could be avoided, yielding an estimated gross cost offset of approximately BRL 19 million.
CONCLUSIONS: A pharmacoeconomic framework incorporating TTNT and NNT enables quantification of the economic value of tafasitamab in 2L R/R FL. By reducing progression to costly subsequent therapies, this strategy has the potential to mitigate overall budget impact across the treatment journey.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE537
Topic
Clinical Outcomes, Economic Evaluation, Health Technology Assessment
Topic Subcategory
Value of Information
Disease
Oncology